Dhoot Transmission IPO GMP: 30% Listing Gain Expected as Molbio Trails at 16%

Dhoot Transmission IPO GMP stood at ₹259 as of August 9, 2026, signaling a 29.74% listing gain over its ₹871 upper price band. That puts the auto components maker well ahead of fellow mainboard debutant Molbio Diagnostics, whose GMP of ₹132 implies a smaller 16.36% premium over its ₹807 upper band. Both issues close for subscription today, Wednesday, August 12, 2026.

Dhoot Transmission’s stronger grey market signal reflects both its EV-linked growth story and heavier analyst conviction. Here’s a complete breakdown of both IPOs and what’s driving the gap in expected listing gains.

Dhoot Transmission IPO: Numbers Behind The 30% Premium

Dhoot Transmission is raising ₹3,066.89 crore through a mix of fresh shares and an offer-for-sale by existing promoters. The issue drew strong anchor investor interest before opening to public bidding.

• Price band: ₹829 to ₹871 per share.
• Fresh issue: ₹1,400 crore; OFS: ₹1,666.89 crore by promoters.
• Anchor investment raised: ₹918.3 crore from investors including SBI Mutual Fund and BlackRock.
• Minimum retail investment: ₹14,807 for a 17-share lot.

Founded in 1998 by Rahul Dhoot, the Aurangabad-headquartered company designs wiring harnesses and electrical distribution systems across two-wheelers, commercial vehicles, and farm equipment. It operates 23 manufacturing plants, with two more currently underway.

Dhoot Transmission IPO is currently the stronger listing-gain candidate of the two, based on the latest grey market premium (GMP), with an implied listing gain of around 30%.https://t.co/swceFnA80T

— NDTV Profit News (@NDTVProfit) August 12, 2026

Subscription Momentum Through Day 2

Dhoot Transmission’s subscription numbers built steadily through the first two days of bidding. Institutional demand lagged behind retail and non-institutional interest heading into today’s final session.

• Day 2 overall subscription: 3.94 times, per HDFC Sky data.
• NII category: 10.62 times subscribed.
• Retail category: 2.97 times subscribed.
• QIB category: just 0.5 times subscribed as of Day 2.

Lower QIB participation through Day 2 is common for mainboard issues, as institutional investors often place larger bids on the final day. Today’s closing session will determine whether Dhoot Transmission’s overall subscription climbs well past its current 3.94x mark.

Molbio Diagnostics IPO: A Smaller, Steadier Premium

Molbio Diagnostics is raising ₹939.70 crore through its own combination of fresh issue and offer-for-sale shares. The diagnostics company’s IPO carries noticeably less grey market enthusiasm than Dhoot Transmission’s.

• Price band: ₹768 to ₹807 per share.
• Fresh issue: ₹200 crore; OFS: ₹739.70 crore.
• Estimated listing price based on GMP: ₹939 per share.
• Analyst recommendations: 9 “Apply” calls out of 15 reviews tracked by Chittorgarh.

Molbio’s smaller GMP reflects more mixed analyst sentiment, with one “Neutral” rating and four reviews left unrated. The company has no direct listed peers in India, which analysts say makes valuation comparisons genuinely harder for prospective investors.

Why Analysts Favor Dhoot Transmission

Bonanza research analyst Khushi Mistry highlighted Dhoot Transmission’s positioning within India’s EV and premiumization trends as a key differentiator. That structural tailwind appears to be supporting the stronger grey market premium.

Dhoot Transmission posted FY26 revenue of ₹4,530 crore, with growing contribution from non-harness products like battery assemblies and chargers. Mistry did flag customer concentration risk, noting dependence on key clients such as Bajaj Auto, TVS, Honda, and Royal Enfield warrants ongoing monitoring even as diversification continues.

Key Dates For Both IPOs

Both issues share a tight, overlapping timeline as they head toward listing. Investors juggling both applications should track each company’s schedule separately.

• Dhoot Transmission allotment: expected Thursday, August 13, 2026.
• Dhoot Transmission listing date: tentatively Monday, August 17, 2026.
• Registrar for Dhoot Transmission: KFin Technologies Limited.
• Molbio Diagnostics: also closes bidding today, August 12, 2026.

Grey market premium remains an unofficial, volatile indicator that can shift sharply before actual listing day. Investors should treat both GMP figures as directional sentiment rather than guaranteed listing outcomes.

Our Take

Dhoot Transmission’s stronger EV-linked growth story and heavier analyst conviction have pushed its GMP well ahead of Molbio Diagnostics, 29.74% versus 16.36%. Both issues close today, with allotment and listing details following over the next week.

Disclaimer:

The content shared by Meyka AI PTY LTD is for research and informational purposes only. Meyka is not a financial advisory service, and the information provided should not be treated as investment or trading advice.